Several studies have shown higher efficacy of GLP-1R-GIPR co-agonists compared to individual agonists, in weight loss and management of type 2 diabetes, while offering a similar safety profile, although the need for personalised treatment selection according to patient characteristics has been highlighted [11,12,13]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.